Behavioral and neurochemical effects of chronic L-DOPA treatment on nonmotor sequelae in the hemiparkinsonian rat

Behavioural Pharmacology

Volumn 21, Issue 7, 2010, Pages 627-637

  Eskow Jaunarajs, Karen L ^a   Dupre, Kristin B ^a   Ostock, Corinne Y ^a   Button, Thomas ^a   Deak, Terrence ^a   Bishop, Christopher ^a  

^a BINGHAMTON UNIVERSITY   (United States)

Author keywords

6 hydroxydopamine; Affect; Anxiety; Depression; Dopamine; L DOPA; Norepinephrine; Parkinson's disease; Rat; Serotonin

Indexed keywords

BENSERAZIDE PLUS LEVODOPA; LEVODOPA; OXIDOPAMINE;

AMYGDALOID NUCLEUS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANXIETY; ARTICLE; CORPUS STRIATUM; DEPRESSION; DRUG EFFECT; FORCED SWIMMING TEST; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HIPPOCAMPUS; LOCOMOTION; MALE; NONHUMAN; PARKINSONISM; PREFRONTAL CORTEX; RAT; SOCIAL INTERACTION; SPRAGUE DAWLEY RAT;

AMYGDALA; ANIMALS; ANXIETY; BEHAVIORAL RESEARCH; BIOGENIC MONOAMINES; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CORPUS STRIATUM; DEPRESSION; DOPAMINE; DOPAMINE AGENTS; HIPPOCAMPUS; HUMANS; LEVODOPA; MALE; MODELS, ANIMAL; MOTOR ACTIVITY; OXIDOPAMINE; PARKINSON DISEASE; PREFRONTAL CORTEX; RATS; RATS, SPRAGUE-DAWLEY;

EID: 77957308414     PISSN: 09558810     EISSN: None     Source Type: Journal    
DOI: 10.1097/FBP.0b013e32833e7e80     Document Type: Article

References (65)

1. Ahlskog JE, Muenter MD (2001). Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature. Mov Disord 16:448-458.
2. Arai A, Tomiyama M, Kannari K, Kimura T, Suzuki C, Watanabe M, et al. (2008). Reuptake of L-DOPA-derived extracellular DA in the striatum of a rodent model of Parkinson's disease via norepinephrine transporter. Synapse 62: 632-635.
3. Arango V, Ernsberger P, Marzuk PM, Chen JS, Tierney H, Stanley M, et al. (1990). Autoradiographic demonstration of increased serotonin 5-HT2 and betaadrenergic receptor binding sites in the brain of suicide victims. Arch Gen Psychiatry 47:1038-1047.
4. Arango V, Ernsberger P, Sved AF, Mann JJ (1993). Quantitative autoradiography of alpha 1- and alpha 2-adrenergic receptors in the cerebral cortex of controls and suicide victims. Brain Res 630:271-282.
5. Barone P, Antonini A, Colosimo C, Marconi R, Morgante L, Avarello TP, et al. (2009). The PRIAMO study: a multicenter assessment of nonmotor symptoms and their impact on quality of life in Parkinson's disease. Mov Disord 24:1641-1649.
6. Beekman AT, Copeland JR, Prince MJ (1999). Review of community prevalence of depression in later life. Br J Psychiatry 174:307-311.
7. Biegon A, Israeli M (1998). Regionally selective increases in beta-adrenergic receptor density in the brains of suicide victims. Brain Res 442:199-203.
8. Borah A, Mohanakumar KP (2007). Long-term L-DOPA treatment causes indiscriminate increase in dopamine levels at the cost of serotonin synthesis in discrete brain regions of rats. Cell Mol Neurobiol 27:985-996.
9. Borbely K, Brooks RA,Wong DF, Burns RS, Cumming P, Gjedde A, et al. (1999). NMSP binding to dopamine and serotonin receptors in MPTP-induced parkinsonism: relation to dopa therapy. Acta Neurol Scand 100:42-52.
10. Braak H, Del Tredici K, Ru'b U, de Vos RA, Jansen Steur EN, Braak E (2003). Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging 24:197-211.
11. Branchi I, D'Andrea I, Armida M, Cassano T, Pè zzola A, Potenza RL, et al. (2008). Nonmotor symptoms in Parkinson's disease: investigating early-phase onset of behavioral dysfunction in the 6-hydroxydopamine-lesioned rat model. J Neurosci Res 86:2050-2061.
12. Carod-Artal FJ, Ziomkowski S, Moura'oMesquitaH, Mart?́nez-Martin P (2008). Anxiety and depression: main determinants of health-related quality of life in Brazilian patients with Parkinson's disease. Parkinsonism Relat Disord 14:102-108.
13. Carta M, Carlsson T, Kirik D, Björklund A (2007). Dopamine released from 5-HT terminals is the cause of L-DOPA-induced dyskinesia in parkinsonian rats. Brain 130:1819-1833.
14. Carta M, Carlsson T, Muñoz A, Kirik D, Björklund A (2008). Serotonin-dopamine interaction in the induction and maintenance of L-DOPA-induced dyskinesias. Prog Brain Res 172:465-478.
15. Choi C, Sohn YH, Lee JH, Kim J (2000). The effect of long-term levodopa therapy on depression level in de novo patients with Parkinson's disease. J Neurol Sci 172:12-16.
16. D'Amato RJ, Zweig RM, Whitehouse PJ, Wenk GL, Singer HS, Mayeux R, et al. (1987). Aminergic systems in Alzheimer's disease and Parkinson's disease. Ann Neurol 22:229-236.
17. Deak T, Bellamy C, D'Agostino LG, Rosanoff M, McElderry NK, Bordner KA (2005). Behavioral responses during the forced swim test are not affected by anti-inflammatory agents or acute illness induced by lipopolysaccharide. Behav Brain Res 160:125-134.
18. Detke MJ, Rickels M, Lucki I (1995). Active behaviors in the rat forced swimming test differentially produced by serotonergic and noradrenergic antidepressants. Psychopharmacology (Berl) 121:66-72.
19. Eskow KL, Dupre KB, Barnum CJ, Dickinson SO, Park JY, Bishop C (2009). The role of the dorsal raphe nucleus in the development, expression, and treatment of L-dopa-induced dyskinesia in hemiparkinsonian rats. Synapse 63:610-620.
20. Everett GM, Borcherding JW (1970). L-DOPA: effect on concentrations of dopamine, norepinephrine, and serotonin in brains of mice. Science 168:847-850.
21. Fetoni V, Soliveri P, Monza D, Testa D, Girotti F (1999). Affective symptoms in multiple system atrophy and Parkinson's disease: response to levodopa therapy. J Neurol Neurosurg Psychiatry 66:541-544.
22. File SE, Seth P (2003). A review of 25 years of the social interaction test. Eur J Pharmacol 463:35-53.
23. Fulceri F, Biagioni F, Lenzi P, Falleni A, Gesi M, Ruggieri S, et al. (2006). Nigrostriatal damage with 6-OHDA: validation of routinely applied procedures. Ann NY Acad Sci 1074:344-348.
24. Garc?́a-Sevilla JA, Escribá PV, Ozaita A, La Harpe R, Walzer C, Eytan A, et al. (1999). Up-regulation of immunolabeled alpha2A- adrenoceptors, Gi coupling proteins, and regulatory receptor kinases in the prefrontal cortex of depressed suicides. J Neurochem 72:282-291.
25. Guiard BP, El Mansari M, Merali Z, Blier P (2008). Functional interactions between dopamine, serotonin and norepinephrine neurons: an in-vivo electrophysiological study in rats with monoaminergic lesions. Int J Neuropsychopharmacol 11:625-639.
26. Halliday GM, Li YW, Blumbergs PC, Joh TH, Cotton RG, Howe PR, et al. (1990). Neuropathology of immunohistochemically identified brainstem neurons in Parkinson's disease. Ann Neurol 27:373-385.
27. Hashiguti H, Nakahara D, Maruyama W, Naoi M, Ikeda T (1993). Simultaneous determination of in vivo hydroxylation of tyrosine and tryptophan in rat striatum by microdialysis-HPLC: relationship between dopamine and serotonin biosynthesis. J Neural Transm Gen Sect 93:213-223.
28. Kannari K, Yamato H, Shen H, Tomiyama M, Suda T, Matsunaga M (2001). Activation of 5-HT(1A) but not 5-HT(1B) receptors attenuates an increase in extracellular dopamine derived from exogenously administered L-DOPA in the striatum with nigrostriatal denervation. J Neurochem 76:1346-1353.
29. Kaya AH, Vlamings R, Tan S, Lim LW, Magill PJ, Steinbusch HW, et al. (2008). Increased electrical and metabolic activity in the dorsal raphe nucleus of Parkinsonian rats. Brain Res 1221:93-97.
30. Kilpatrick IC, Jones MW, Phillipson OT (1986). A semiautomated analysis method for catecholamines, indoleamines, and some prominent metabolites in microdissected regions of the nervous system: an isocratic HPLC technique employing coulometric detection and minimal sample preparation. J Neurochem 46:1865-1876.
31. Kim HJ, Park SY, Cho YJ, Hong KS, Cho JY, Seo SY, et al. (2009). Nonmotor symptoms in de novo Parkinson disease before and after dopaminergic treatment. J Neurol Sci 287:200-204.
32. Kuhn DM, Arthur RE Jr (1999). L-DOPA-quinone inactivates tryptophan hydroxylase and converts the enzyme to a redox-cycling quinoprotein. Brain Res Mol Brain Res 73:78-84.
33. Kulisevsky J, Pascual-Sedano B, Barbanoj M, Gironell A, Pagonabarraga J, Garc?́a-Sánchez C (2007). Acute effects of immediate and controlled-release levodopa on mood in Parkinson's disease: a double-blind study. Mov Disord 22:62-67.
34. Leentjens AF, Van den Akker M, Metsemakers JF, Lousberg R, Verhey FR (2003). Higher incidence of depression preceding the onset of Parkinson's disease: a register study. Mov Disord 18:414-418.
35. Lucki I (1997). The forced swimming test as a model for core and component behavioral effects of antidepressant drugs. Behav Pharmacol 8:523-532.
36. Maricle RA, Nutt JG, Valentine RJ, Carter JH (1995). Dose-response relationship of levodopa with mood and anxiety in fluctuating Parkinson's disease: a double-blind, placebo-controlled study. Neurology 45:1757-1760.
37. Maricle RA, Valentine RJ, Carter J, Nutt JG (1998). Mood response to levodopa infusion in early Parkinson's disease. Neurology 50:1890-1892.
38. McKinlay A, Grace RC, Dalrymple-Alford JC, Anderson T, Fink J, Roger D (2008). A profile of neuropsychiatric problems and their relationship to quality of life for Parkinson's disease patients without dementia. Parkinsonism Relat Disord 14:37-42.
39. Menza MA, Sage J, Marshall E, Cody R, Duvoisin R (1990). Mood changes and 'on-off' phenomena in Parkinson's disease. Mov Disord 5:148-151.
40. Naivalles S, Bioulac B, Gross C, De Deurwaedere P (2010a). Serotonergic neurons mediate ectopic release of dopamine induced by L-DOPA in a rat model of Parkinson's disease. Neurobiol Dis 38:136-143.
41. Naivalles S, Benazzouz A, Bioulac B, Gross C, De Deurwaedere P (2010b). High-frequency stimulation of the subthalamic nucleus and L-3,4- dihydroxyphenylalanine inhibit in vivo serotonin release in the prefrontal cortex and hippocampus in a rat model of Parkinson's disease. J Neurosci 30:2356-2364.
42. Nè gre-Pagès L, Grandjean H, Lapeyre-Mestre M, Montastruc JL, Fourrier A, Lépine JP, et al. (2010). Anxious and depressive symptoms in Parkinson's disease: the French cross-sectional DoPaMiP study. Mov Disord 25:157-166.
43. Ng KY, Chase TN, Colburn RW, Kopin IJ (1970). L-Dopa-induced release of cerebral monoamines. Science 170:76-77.
44. Nilsson FM, Kessing LV, Bolwig TG (2001). Increased risk of developing Parkinson's disease for patients with major affective disorder: a register study. Acta Psychiatr Scand 104:380-386.
45. Paxinos G, Watson W (1998). The rat brain in stereotaxic coordinates. 4th ed. San Diego: Academic Press.
46. Pierucci M, Di Matteo V, Benigno A, Crescimanno G, Esposito E, Di Giovanni G (2009). The unilateral nigral lesion induces dramatic bilateral modification on rat brain monoamine neurochemistry. Ann NY Acad Sci 1155:316-323.
47. Prut L, Belzung C (2003). The open field as a paradigm to measure the effects of drugs on anxiety-like behaviors: a review. Eur J Pharmacol 463:3-33.
48. Remy P, Doder M, Lees A, Turjanski N, Brooks D (2005). Depression in Parkinson's disease: loss of dopamine and noradrenaline innervation in the limbic system. Brain 128:1314-1322.
49. Ressler KJ, Nemeroff CB (2000). Role of serotonergic and noradrenergic systems in the pathophysiology of depression and anxiety disorders. Depress Anxiety 12 (Suppl 1):2-19.
50. Richard IH, Schiffer RB, Kurlan R (1996). Anxiety and Parkinson's disease. J Neuropsychiatry Clin Neurosci 8:383-392.
51. Richard IH, Justus AW, Kurlan R (2001). Relationship between mood and motor fluctuations in Parkinson's disease. J Neuropsychiatry Clin Neurosci 13:35-41.
52. Richard IH, Frank S, McDermott MP, Wang H, Justus AW, Ladonna KA, et al. (2004). The ups and downs of Parkinson disease: a prospective study of mood and anxiety fluctuations. Cogn Behav Neurol 17:201-207.
53. Robinson DL, Venton BJ, Heien ML,Wightman RM (2003). Detecting subsecond dopamine release with fast-scan cyclic voltammetry in vivo. Clin Chem 49:1763-1773.
54. Sato S, Koitabashi T, Koshiro A (1994). Pharmacokinetic and pharmacodynamic studies of L-dopa in rats. I. Pharmacokinetic analysis of L-dopa in rat plasma and striatum. Biol Pharm Bull 17:1616-1621.
55. Schrag A (2006). Quality of life and depression in Parkinson's disease. J Neurol Sci 248:151-157.
56. Srinivasan J, Schmidt WJ (2004). Behavioral and neurochemical effects of noradrenergic depletions with N-(2-chloroethyl)-N-ethyl-2-bromobenzylamine in 6-hydroxydopamine-induced rat model of Parkinson's disease. Behav Brain Res 151:191-199.
57. Tadaiesky MT, Dombrowski PA, Figueiredo CP, Cargnin-Ferreira E, Da Cunha C, Takahashi RN (2008). Emotional, cognitive and neurochemical alterations in a premotor stage model of Parkinson's disease. Neuroscience 156:830-840.
58. Wang S, Zhang QJ, Liu J, Wu ZH, Wang T, Gui ZH, et al. (2009a). Unilateral lesion of the nigrostriatal pathway induces an increase of neuronal firing of the midbrain raphe nuclei 5-HT neurons and a decrease of their response to 5-HT(1A) receptor stimulation in the rat. Neuroscience 159:850-861.
59. Wang T, Zhang QJ, Liu J, Wu ZH, Wang S (2009b). Firing activity of locus coeruleus noradrenergic neurons increases in a rodent model of Parkinsonism. Neurosci Bull 5:15-20.
60. Weintraub D, Moberg PJ, Duda JE, Katz IR, Stern MB (2004). Effect of psychiatric and other nonmotor symptoms on disability in Parkinson's disease. J Am Geriatr Soc 52:784-788.
61. Winter C, von Rumohr A, Mundt A, Petrus D, Klein J, Lee T, et al. (2007). Lesions of dopaminergic neurons in the substantia nigra pars compacta and in the ventral tegmental area enhance depressive-like behavior in rats. Behav Brain Res 184:133-141.
62. Wragg RE, Jeste DV (1989). Overview of depression and psychosis in Alzheimer's disease. Am J Psychiatry 146:577-587.
63. Yamamoto M (2001). Depression in Parkinson's disease: its prevalence, diagnosis, and neurochemical background. J Neurol 248:III5-III11.
64. Young AM (1993). Intracerebral microdialysis in the study of physiology and behavior. Rev Neurosci 4:373-395.
65. Zhang QJ, Gao R, Liu J, Liu YP,Wang S (2007). Changes in the firing activity of serotonergic neurons in the dorsal raphe nucleus in a rat model of Parkinson's disease. Sheng Li Xue Bao 59:183-189.